Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy ParticipantsOlena Anoshchenko, Rita Humeniuk, Heng Chen et al.|Clinical Pharmacology & Therapeutics|2024Cited by 12
539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for ObeldesivirJared Pitts, John P. Bilello, Darius Babusis et al.|Open Forum Infectious Diseases|2023Cited by 3